



WE TRANSFORM YOUR MOLECULE INTO A REGISTERED DRUG

Debiopharm Group™ is a Swiss-based global bio-pharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs. Oncology is the group's main area of expertise. In addition, Debiopharm develops or co-develops drugs for specific indications in the following therapeutic areas: infectious diseases, pain, metabolic diseases and immune-mediated diseases.

Debiopharm's core activities consist in :

- Licensing-in new molecules presenting potentially superior therapeutic properties. This takes place following a robust search and evaluation process;
- Taking the licensed-in molecules through the entire development process, i.e. pre-clinical and clinical development, formulation, manufacturing and registration;
- Selecting the best licensee(s) for the worldwide commercialisation of the registered drugs.

Debiopharm has developed extensive expertise in other areas by carrying out :

- Applied research in the field of peptides, e.g. to develop molecules with an enhanced safety and/or efficacy profile;
- Drug delivery research, for instance to facilitate the administration of drugs to patients in emerging countries for whom a daily pill or a daily injection may not be practical;
- Life-cycle management from a relatively early stage;
- Industrial manufacturing involving the company's own proprietary technology. Debiopharm has FDA-approved clinical scale-GMP manufacturing facilities in Valais, Switzerland.

In addition, Debiopharm has been involved in the field of companion diagnostics since 2008, with a view to progressing in the area of personalised medicine.

Debiopharm has funded a chair at the EPFL (Ecole Polytechnique Fédérale de Lausanne) and grants each year three scientific awards: two in Switzerland (EPFL and Haute Ecole valaisanne), and one in Japan (JCA-Mauvrenay Award).

Debiopharm has a team of 300 professionals from over 20 different countries; and it is advised by a network of international consultants with scientific expertise in all relevant areas.

Debiopharm invests in the molecules that it licences in while bearing the entire financial risk of the development process. Debiopharm's main source of income consists in royalty payments, part of which is shared with the originators of the molecules.

Debiopharm has successfully brought five products to market, namely :

- :: Eloxatin®/Elplat®, a DACH platin for the treatment of colorectal cancer. The active substance of this drug is oxaliplatin;
- :: Decapeptyl®/Trelstar®/Pamorelin®, a LHRH agonist for the treatment of prostate cancer, endometriosis and precocious puberty in a 1-month-formulation. The active substance of this drug is triptorelin;
- :: Decapeptyl®/Trelstar®/Pamorelin® in a 3-month-formulation;
- :: Decapeptyl®/Trelstar® in a 6-month-formulation;
- :: Moapar®/Salvacyl® 3-month, a LHRH agonist for the treatment of sexual deviations. The active substance of this drug is triptorelin.

Debiopharm's latest achievements include but are not limited to partnerships with Pfizer and with Novartis, which illustrate the complementarity between the leading pharmaceutical companies and Debiopharm.

Debiopharm Group™ was founded in 1979 and is headquartered in Lausanne, Switzerland.